Tag Archives: thromboprophylaxis

Introduction Adults living with a Fontan circulation are at persistently elevated potential risk of both thrombosis and bleeding. The Fontan procedure is a palliative surgical strategy for patients with univentricular congenital heart disease, which reroutes systemic venous return directly to the pulmonary arteries.1 This unique physiology leads to a non-pulsatile, low-pressure pulmonary circulation, which contributes to chronic venous congestion, blood stasis and altered flow dynamics. These factors, alongside endothelial dysfunction and potential coagulation abnormalities, create a prothrombotic environment.2 Increased bleeding risk can ari

When the NOACs (novel oral anticoagulants) were introduced over three years ago, they promised to revitalise the management of conditions such as atrial fibrillation (AF), venous thromboembolism (VTE) and thromboprophylaxis after major joint replacement surgery. Rivaroxaban is currently available in multiple indications, including (but not limited to): prevention of stroke and systemic embolism in adult patients with non-valvular AF, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. For decades anticoagulant therapy in these conditions had relied on the vitamin K antagon